Literature DB >> 19479878

Intervention of an inflammation amplifier, triggering receptor expressed on myeloid cells 1, for treatment of autoimmune arthritis.

Yousuke Murakami1, Tohru Akahoshi, Naoko Aoki, Masayasu Toyomoto, Nobuyuki Miyasaka, Hitoshi Kohsaka.   

Abstract

OBJECTIVE: Triggering receptor expressed on myeloid cells 1 (TREM-1) is inducible on monocyte/macrophages and neutrophils and accelerates tissue destruction by propagating inflammatory responses in disease related to bacterial infections. Its blockade rescues the hosts in murine models of sepsis, to clear the bacteria without impairing the host defense. The aim of this study was to investigate the involvement of TREM-1 in an autoimmune, noninfectious disease.
METHODS: Synovial tissue specimens from the joints of patients with rheumatoid arthritis (RA) and the joints of mice with collagen-induced arthritis (CIA) were examined for TREM-1 expression, using flow cytometric analysis. Expression of TREM-1 on macrophages was induced by lipopolysaccharide, with or without a cyclooxygenase inhibitor. Rheumatoid synovial cells were stimulated with agonistic anti-TREM-1 antibodies. Recombinant adenovirus encoding the extracellular domain of TREM-1 fused with IgG-Fc (AxCATREM-1 Ig) or synthetic TREM-1 antagonistic peptides were injected to treat CIA, and the clinical manifestations of the antigen-specific T cell and B cell responses were evaluated.
RESULTS: TREM-1 was expressed on CD14+ cells in rheumatoid synovial tissue and synovial macrophages from mice with CIA. Unlike murine macrophages, human monocyte/macrophages did not depend on prostaglandin E2 for up-regulation of TREM-1. Agonistic anti-TREM-1 antibodies promoted tumor necrosis factor alpha production from rheumatoid synovial cells. Blockade of TREM-1 using AxCATREM-1 Ig and antagonistic peptides ameliorated CIA without affecting the serum levels of anti-type II collagen antibodies or the proliferative responses of splenocytes to type II collagen.
CONCLUSION: TREM-1 ligation contributes to the pathology of autoimmune arthritis. The results of this study implied that blockade of TREM-1 could be a new approach to rheumatic diseases that is safer than the presently available immunosuppressive treatments.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19479878     DOI: 10.1002/art.24554

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  27 in total

Review 1.  New therapeutic strategies targeting transmembrane signal transduction in the immune system.

Authors:  Alexander B Sigalov
Journal:  Cell Adh Migr       Date:  2010-04-24       Impact factor: 3.405

2.  Correlation between triggering receptor expressed on myeloid cells-1 and clinical disease activity in Chinese patients with ulcerative colitis.

Authors:  Shulan Zhang; Jing Luo; Bingbing Shen; Lijun Li; Chaojun Hu; Ping Li; Chuiwen Deng; Fengchun Zhang; Jiaming Qian; Yongzhe Li
Journal:  Int J Clin Exp Med       Date:  2015-02-15

3.  The SCHOOL of nature: III. From mechanistic understanding to novel therapies.

Authors:  Alexander B Sigalov
Journal:  Self Nonself       Date:  2010-06-11

4.  Triggering receptor expressed on myeloid cells-1 as a new therapeutic target during inflammatory diseases.

Authors:  Marc Derive; Frédéric Massin; Sébastien Gibot
Journal:  Self Nonself       Date:  2010-07-02

5.  Repetitive Exposure of IL-17 Into the Murine Air Pouch Favors the Recruitment of Inflammatory Monocytes and the Release of IL-16 and TREM-1 in the Inflammatory Fluids.

Authors:  Francesco Maione; Asif Jilani Iqbal; Federica Raucci; Michal Letek; Martina Bauer; Fulvio D'Acquisto
Journal:  Front Immunol       Date:  2018-11-30       Impact factor: 7.561

6.  TREM-1-accentuated lung injury via miR-155 is inhibited by LP17 nanomedicine.

Authors:  Zhihong Yuan; Mansoor Syed; Dipti Panchal; Myungsoo Joo; Chetna Bedi; Sokbee Lim; Hayat Onyuksel; Israel Rubinstein; Marco Colonna; Ruxana T Sadikot
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-12-18       Impact factor: 5.464

7.  Blockade of TREM-1 prevents vitreoretinal neovascularization in mice with oxygen-induced retinopathy.

Authors:  Modesto A Rojas; Zu T Shen; Ruth B Caldwell; Alexander B Sigalov
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-05-03       Impact factor: 5.187

8.  Serum soluble triggering receptor on myeloid cells-1 (sTREM-1) is elevated in systemic lupus erythematosus but does not distinguish between lupus alone and concurrent infection.

Authors:  Yair Molad; Elisheva Pokroy-Shapira; Tania Kaptzan; Assaf Monselise; Michal Shalita-Chesner; Yehudit Monselise
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

9.  TREM-1 and pentraxin-3 plasma levels and their association with obstructive sleep apnea, obesity, and endothelial function in children.

Authors:  Jinkwan Kim; David Gozal; Rakesh Bhattacharjee; Leila Kheirandish-Gozal
Journal:  Sleep       Date:  2013-06-01       Impact factor: 5.849

10.  A novel ligand-independent peptide inhibitor of TREM-1 suppresses tumor growth in human lung cancer xenografts and prolongs survival of mice with lipopolysaccharide-induced septic shock.

Authors:  Alexander B Sigalov
Journal:  Int Immunopharmacol       Date:  2014-05-14       Impact factor: 4.932

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.